| 26.09 15:22 | dpa-AFX: Vertex Says Health Canada Accepts NDS For Triple Combination To Treat Cystic Fibrosis |
| 26.09 15:02 | dpa-AFX: *VERTEX ANNOUNCES HEALTH CANADA ACCEPTANCE OF NEW DRUG SUBMISSION FOR NEXT-GEN CYSTIC FIBROSIS TREATMENT |
| 26.09 04:41 | dpa-AFX: Health Canada Oks Vertex's CASGEVY, First CRISPR/Cas9 Gene-Edited Therapy For Sickle Cell Disease |
| 04.08 11:00 | dpa-AFX: Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid |
| 02.08 00:07 | dpa-AFX: Vertex Pharmaceuticals Inc. Q2 Earnings Summary |
| 01.08 23:51 | dpa-AFX: *VERTEX Q2 LOSS/SHARE $13.92 VS. PROFIT $3.52 YEAR AGO |
| 15.07 15:21 | dpa-AFX: Vertex Pharma Announces Expanded Approval Of TRIKAFTA By Health Canada |
| 15.07 15:07 | dpa-AFX: *VERTEX'S TRIKAFTA APPROVED BY HEALTH CANADA FOR CYSTIC FIBROSIS PATIENTS AGED 2+ WITH RARE MUTATIONS |
| 02.07 15:40 | dpa-AFX: Vertex Pharma: Vanza Triple Granted Priority Review |
| 02.07 15:23 | dpa-AFX: *VERTEX ANNOUNCES FDA ACCEPTANCE OF NDA FOR TRIPLE COMBINATION TREATMENT FOR CYSTIC FIBROSIS |
| 27.06 08:45 | dpa-AFX: *REDBURN STARTS VERTEX WITH 'BUY' - PRICE TARGET 554 USD |
| 27.06 08:45 | dpa-AFX: *REDBURN STARTET VERTEX MIT 'BUY' - ZIEL 554 USD |
| 07.06 14:09 | dpa-AFX: These Biotech Stocks Hit New Highs, Did You Reap The Rewards? |
| 15.05 16:33 | dpa-AFX: *VERTEX ELECTS JENNIFER SCHNEIDER AS INDEPENDENT DIRECTOR |
| 06.05 22:13 | dpa-AFX: Vertex Pharmaceuticals Inc. Q1 Profit Increases, beats estimates |
| 06.05 22:06 | dpa-AFX: *VERTEX PHARMA Q1 NET PRODUCT REVENUES $2.69 BLN VS. $2.37 BLN LAST YEAR |
| 06.05 22:06 | dpa-AFX: *VERTEX PHARMA Q1 NET INCOME $1.10 BLN VS. $699.8 MLN PRIOR YEAR |
| 06.05 22:06 | dpa-AFX: *VERTEX PHARMA Q1 EPS $4.21 VS. $2.69 YEAR AGO |
| 23.04 07:00 | dpa-AFX: Vertex Pharma Obtains Exclusive License To TreeFrog's Cell Manufacturing Technology, C-Stem |
| 23.04 06:53 | dpa-AFX: *VERTEX PHARMA OBTAINS EXCLUSIVE LICENSE TO TREEFROG'S PROPRIETARY CELL MANUFACTURING TECHNOLOGY, C-STEM |
|
|
